GEN Exclusives

More »

GEN News Highlights

More »
Aug 30, 2012

Life and Sino Sign Distribution and Development Pact

  • Life Technologies and China’s Sino Biological signed a worldwide product distribution and development agreement, through which Life will distribute its new partner’s portfolio of recombinant proteins, antibodies, and Elisa kits worldwide, including over 2,000 recombinant proteins and 3,000 antibody products. The two firms will also work together to develop new proteomics products for applications in areas including flow cytometry and imaging.

    “Sino Biological’s mission is to develop the best quality biological tools to assist scientists,” comments Liangzhi Xi, Ph.D., president and CEO at Sino. “Combining our state-of-the-art disruptive technologies in recombinant protein production and antibody development with Life Technologies’ innovative product development and worldwide marketing will allow us to bring powerful research tools to scientists solving critical puzzles in life science research and drug discovery.”

    Established in 2007, Sino is a major manufacturer and supplier of cDNA, recombinant protein, and antibody products to the biomedical and pharmaceutical research industries. The firm says it has the in-house capability and capacity to produce over 1,000 new recombinant proteins per year in bulk, and has commercialized over 10,000 products. 


Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?